Research Progress on Exportin 1 Inhibitor Selinexor in Treatment of Lymphoma
Exportin 1(XPO1)is a major nuclear export protein in cells,responsible for the export-ing a large number of proteins and RNA from the nucleus to the cytoplasm.XP01 is overex-pressed in various malignant tumors,leading to uneven distribution of regulatory proteins within cells and uncontrolled tumor cell proliferation.Therefore,XPO1 would be a potential target for treatment of multiple types of cancer.Selinexor is the first marketed XPO1 inhibitor,exhibiting an excellent antitumor activity in various solid tumors and hematological malignancies.The US Food and Drug Administration has approved its use for the treatment of relapse and/or refractory mul-tiple myeloma and diffuse large B-cell lymphoma.This paper reviews the current status of preclini-cal research and clinical application of selinexor in treatment for lymphoma.
selective inhibitor of nuclear exportexportin 1selinexorlymphomatargeted therapy
NETL
NSTL
万方数据
